PE20201167A1 - Metodos de inactivacion de virus utilizando n-metilglutamida y sus derivados - Google Patents
Metodos de inactivacion de virus utilizando n-metilglutamida y sus derivadosInfo
- Publication number
- PE20201167A1 PE20201167A1 PE2020000381A PE2020000381A PE20201167A1 PE 20201167 A1 PE20201167 A1 PE 20201167A1 PE 2020000381 A PE2020000381 A PE 2020000381A PE 2020000381 A PE2020000381 A PE 2020000381A PE 20201167 A1 PE20201167 A1 PE 20201167A1
- Authority
- PE
- Peru
- Prior art keywords
- solution
- interest
- methods
- viruses
- biological product
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
- A01N37/20—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof containing the group, wherein Cn means a carbon skeleton not containing a ring; Thio analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13061—Methods of inactivation or attenuation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta divulgacion se refiere a metodos para usar en la inactivacion de virus. Los metodos de inactivacion de virus con N-metilglucamidas son aplicables al proceso de purificacion de medicamentos biologicamente activos como subunidades de proteinas, proteinas (enzimas, factores, etc.), proteinas recombinantes, anticuerpos, vacunas o productos terapeuticos geneticos. Los detergentes utilizados en este metodo se basan en multiples homologos de N-metilglucamida, que consisten en un resto de glucosa hidrofilica y una cola de acido graso hidrofobico, unidos por un enlace amida. Ademas, estos detergentes a base de azucar son no ionicos por naturaleza, lo que no interrumpe la proteina del farmaco, los productos biologicos del plasma, la vacuna viral sin envoltura, o las particulas virales adenoasociadas. Un metodo para purificar una solucion de un producto biologico de interes que tiene un contaminante de virus envuelto no identificado, que incluye incubar una solucion de producto biologico de interes con una solucion estandar, inactivando cualquier posible contaminante de virus envuelto presente en la solucion de la etapa (a), midiendo el virus inactivado presente en la solucion final de la etapa (b), incubando una solucion de producto biologico separado de interes, con una solucion de N-metilglucamida, midiendo el virus inactivado presente en la solucion final de la etapa (d), y comparando los resultados de la solucion final con las soluciones de la etapa (c) y la etapa (e).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762559812P | 2017-09-18 | 2017-09-18 | |
| PCT/US2018/050579 WO2019055463A1 (en) | 2017-09-18 | 2018-09-12 | METHODS OF INACTIVATING VIRUSES USING N-METHYLGLUCAMIDE AND ITS DERIVATIVES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20201167A1 true PE20201167A1 (es) | 2020-10-28 |
Family
ID=63762999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000381A PE20201167A1 (es) | 2017-09-18 | 2018-09-12 | Metodos de inactivacion de virus utilizando n-metilglutamida y sus derivados |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11564392B2 (es) |
| EP (1) | EP3684921A1 (es) |
| JP (2) | JP7317005B2 (es) |
| KR (1) | KR20200052370A (es) |
| CN (1) | CN111108193A (es) |
| AU (1) | AU2018331357A1 (es) |
| BR (1) | BR112020005229A2 (es) |
| CA (1) | CA3075853A1 (es) |
| IL (1) | IL273229A (es) |
| MX (1) | MX2020002939A (es) |
| PE (1) | PE20201167A1 (es) |
| SG (1) | SG11202002449PA (es) |
| TW (1) | TWI834623B (es) |
| WO (1) | WO2019055463A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020005229A2 (pt) * | 2017-09-18 | 2020-09-24 | Bayer Healthcare Llc | métodos de inativação de vírus usando n-metilglucamida e seus derivados |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| DE3704550A1 (de) * | 1987-02-13 | 1988-08-25 | Behringwerke Ag | Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen |
| DE4103800A1 (de) | 1990-09-27 | 1992-04-02 | Helmuth Schmoock | Folie |
| DE4125625C2 (de) * | 1991-08-02 | 1999-12-02 | Octapharma Ag Glarus | Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen |
| WO1994013329A1 (de) * | 1992-12-16 | 1994-06-23 | Immuno Aktiengesellschaft | Verfahren zur herstellung eines virussicheren biologischen präparates |
| US5695928A (en) | 1993-12-10 | 1997-12-09 | Novartis Corporation | Rapid immunoassay for detection of antibodies or antigens incorporating simultaneous sample extraction and immunogenic reaction |
| DE19528221C2 (de) | 1995-08-01 | 1998-10-22 | Blutspendedienst Der Drk Lande | Verfahren zur Herstellung eines virussicheren, therapeutischen Präparates aus Humanplasma |
| CA2175719A1 (en) | 1996-05-03 | 1997-11-04 | Brian J. Underdown | Compositions and methods for protection against immunologically diverse isolates of influenza virus |
| US6093743A (en) | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| MXPA00006196A (es) | 1998-10-23 | 2003-07-21 | Idea Ag | Metodo para desarrollar, evaluar y utilizar asociaciones de macromoleculas y agregados complejos para obtener mejores tasas de asociacion/desasociacion controlable y carga efectiva. |
| WO2002065125A1 (en) | 2001-02-13 | 2002-08-22 | Invitrogen Corporation | Methods and compositions for isolation of biological macromolecules |
| US8546075B2 (en) | 2003-10-28 | 2013-10-01 | Advanced Life Science Institute, Inc. | Method of detecting hepatitis C virus |
| JP4131850B2 (ja) | 2003-12-04 | 2008-08-13 | アークレイ株式会社 | インフルエンザウイルスの免疫学的測定方法 |
| ATE493659T1 (de) | 2004-05-19 | 2011-01-15 | Advanced Life Science Inst Inc | Verfahren zum nachweis von hepatitis-b-virus |
| WO2006033368A1 (ja) | 2004-09-22 | 2006-03-30 | Advanced Life Science Institute, Inc. | Ｂ型肝炎ウイルスｓ抗原の検出法 |
| CA2766173A1 (en) * | 2006-12-15 | 2008-06-26 | Schering-Plough Ltd. | Method for replicating influenza virus in culture |
| WO2008076371A2 (en) | 2006-12-15 | 2008-06-26 | Schering-Plough Ltd. | Method for replicating influenza virus in culture |
| CN101081298A (zh) | 2007-06-26 | 2007-12-05 | 陈少莺 | 一种猪伪狂犬病新型亚单位疫苗制备方法 |
| EP2280690A2 (en) | 2008-04-18 | 2011-02-09 | Nanobio Corporation | Methods for treating herpes virus infections |
| US9144606B2 (en) | 2008-04-21 | 2015-09-29 | Nanobio Corporation | Nanoemulsion influenza vaccine |
| WO2010014903A1 (en) | 2008-07-31 | 2010-02-04 | Massachusetts Institute Of Technology | Multiplexed olfactory receptor-based microsurface plasmon polariton detector |
| JP2010077091A (ja) | 2008-09-26 | 2010-04-08 | Beacle Inc | Ｂ型肝炎ウイルスタンパク質中空バイオナノ粒子とリポソームを用いたｓｉＲＮＡの内包と細胞選択的なｓｉＲＮＡの導入方法 |
| EP2729169A1 (en) | 2011-07-06 | 2014-05-14 | Nanobio Corporation | Human respiratory syncytial virus vaccine |
| WO2014025771A2 (en) | 2012-08-06 | 2014-02-13 | Biogen Idec Ma Inc. | Methods and compositions for inactivating enveloped viruses |
| LT3043814T (lt) | 2013-09-13 | 2021-02-25 | Salipro Biotech AB | Antigenas ir jo gamybos būdas |
| HRP20240222T1 (hr) * | 2013-11-15 | 2024-04-26 | F. Hoffmann - La Roche Ag | Postupci inaktivacije virusa korištenjem ekološki prihvatljivih deterdženata |
| JP2016182112A (ja) | 2015-03-25 | 2016-10-20 | 東ソー株式会社 | ウイルスからの核酸抽出試薬 |
| BR112020005229A2 (pt) * | 2017-09-18 | 2020-09-24 | Bayer Healthcare Llc | métodos de inativação de vírus usando n-metilglucamida e seus derivados |
-
2018
- 2018-09-12 BR BR112020005229-9A patent/BR112020005229A2/pt unknown
- 2018-09-12 AU AU2018331357A patent/AU2018331357A1/en active Pending
- 2018-09-12 US US16/646,600 patent/US11564392B2/en active Active
- 2018-09-12 CN CN201880060493.4A patent/CN111108193A/zh active Pending
- 2018-09-12 EP EP18782592.2A patent/EP3684921A1/en active Pending
- 2018-09-12 CA CA3075853A patent/CA3075853A1/en active Pending
- 2018-09-12 TW TW107132077A patent/TWI834623B/zh active
- 2018-09-12 KR KR1020207010807A patent/KR20200052370A/ko not_active Application Discontinuation
- 2018-09-12 MX MX2020002939A patent/MX2020002939A/es unknown
- 2018-09-12 WO PCT/US2018/050579 patent/WO2019055463A1/en unknown
- 2018-09-12 JP JP2020515732A patent/JP7317005B2/ja active Active
- 2018-09-12 SG SG11202002449PA patent/SG11202002449PA/en unknown
- 2018-09-12 PE PE2020000381A patent/PE20201167A1/es unknown
-
2020
- 2020-03-11 IL IL273229A patent/IL273229A/en unknown
-
2022
- 2022-10-28 US US17/975,645 patent/US20230143494A1/en not_active Abandoned
-
2023
- 2023-07-18 JP JP2023116731A patent/JP2023139096A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200052370A (ko) | 2020-05-14 |
| JP2023139096A (ja) | 2023-10-03 |
| JP7317005B2 (ja) | 2023-07-28 |
| CA3075853A1 (en) | 2019-03-21 |
| BR112020005229A2 (pt) | 2020-09-24 |
| US20230143494A1 (en) | 2023-05-11 |
| EP3684921A1 (en) | 2020-07-29 |
| TWI834623B (zh) | 2024-03-11 |
| MX2020002939A (es) | 2020-07-22 |
| TW201925163A (zh) | 2019-07-01 |
| SG11202002449PA (en) | 2020-04-29 |
| AU2018331357A1 (en) | 2020-04-02 |
| RU2020113752A (ru) | 2021-10-20 |
| JP2020533987A (ja) | 2020-11-26 |
| US11564392B2 (en) | 2023-01-31 |
| US20200260727A1 (en) | 2020-08-20 |
| WO2019055463A1 (en) | 2019-03-21 |
| CN111108193A (zh) | 2020-05-05 |
| RU2020113752A3 (es) | 2022-04-22 |
| IL273229A (en) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Perng et al. | ISG15 in antiviral immunity and beyond | |
| ES2950887T3 (es) | Purificación del Virus Zika | |
| Rajsbaum et al. | Unanchored K48-linked polyubiquitin synthesized by the E3-ubiquitin ligase TRIM6 stimulates the interferon-IKKε kinase-mediated antiviral response | |
| Cheong et al. | Influenza A virus NS1 protein inhibits the NLRP3 inflammasome | |
| CO2020004738A2 (es) | Variantes de cápsides de virus adenoasociados y métodos de uso de estas | |
| CY1124689T1 (el) | Trans-αντιγραφοymeno rna | |
| CL2018002825A1 (es) | Vacuna contra vrs | |
| EA202092808A1 (ru) | Вакцины на основе наночастиц с новыми структурными компонентами | |
| CL2013003248A1 (es) | Composición inmunogenica que comprende una glucoproteina g de los virus hendra y nipah y un complejo inmunoestimulante; método para producir una respuesta de anticuerpo neutralizante contra un virus hendra y/o nipah en un sujeto. | |
| BR112016007868A2 (pt) | vacinas contra o vírus de epstein-barr | |
| BR112015022790A8 (pt) | molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral | |
| BR112018003316A2 (pt) | compostos e métodos para entrega transmembrana de moléculas | |
| CO2018007203A2 (es) | Focalización de péptidos para dirigir virus adenoasociados (aavs) | |
| Kwon et al. | An RNA aptamer that specifically binds to the glycosylated hemagglutinin of avian influenza virus and suppresses viral infection in cells | |
| ATE494906T1 (de) | Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna | |
| Komarova et al. | Proteomic analysis of virus-host interactions in an infectious context using recombinant viruses | |
| BR112017014219A2 (pt) | vacinas à base de nanopartículas multivalentes | |
| Kell et al. | RIG-I-like receptor activation drives type I IFN and antiviral signaling to limit Hantaan orthohantavirus replication | |
| El-Sayed et al. | Sero-prevalence of avian influenza in animals and human in Egypt. | |
| CL2020001901A1 (es) | Vacunas contra virus de la gripe y usos de las mismas. | |
| Zhang et al. | FAT10 is critical in influenza A virus replication by inhibiting type I IFN | |
| Si et al. | Self-assembling short immunostimulatory duplex RNAs with broad-spectrum antiviral activity | |
| PE20201167A1 (es) | Metodos de inactivacion de virus utilizando n-metilglutamida y sus derivados | |
| Guo et al. | DEF cell-derived exosomal miR-148a-5p promotes DTMUV replication by negative regulating TLR3 expression | |
| AR104554A1 (es) | Sistema de control del proceso de regulación y control de una planta de estructura modular para la obtención de productos biofarmacéuticos y biológicos macromoleculares |